Rice Hall James & Associates LLC cut its stake in OmniAb, Inc. (NASDAQ:OABI - Free Report) by 2.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,649,007 shares of the company's stock after selling 73,314 shares during the period. Rice Hall James & Associates LLC owned about 1.88% of OmniAb worth $9,377,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Palumbo Wealth Management LLC boosted its holdings in OmniAb by 12.5% in the third quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company's stock valued at $104,000 after purchasing an additional 2,744 shares during the period. SG Americas Securities LLC boosted its holdings in OmniAb by 16.5% in the fourth quarter. SG Americas Securities LLC now owns 40,609 shares of the company's stock valued at $144,000 after purchasing an additional 5,751 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in OmniAb by 64.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company's stock valued at $96,000 after purchasing an additional 8,909 shares during the period. Woodstock Corp lifted its holdings in OmniAb by 1.2% during the 4th quarter. Woodstock Corp now owns 802,578 shares of the company's stock worth $2,841,000 after buying an additional 9,725 shares during the last quarter. Finally, Choreo LLC purchased a new stake in OmniAb during the 4th quarter worth about $41,000. 72.08% of the stock is currently owned by hedge funds and other institutional investors.
OmniAb Stock Performance
NASDAQ OABI traded down $0.23 during trading on Friday, reaching $3.65. 635,557 shares of the company's stock were exchanged, compared to its average volume of 508,669. The company has a 50 day moving average price of $3.48 and a two-hundred day moving average price of $3.90. OmniAb, Inc. has a 1 year low of $3.10 and a 1 year high of $6.55. The stock has a market cap of $515.45 million, a P/E ratio of -5.89 and a beta of -0.12.
Insider Transactions at OmniAb
In other news, insider Charles S. Berkman sold 8,215 shares of OmniAb stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total transaction of $30,231.20. Following the sale, the insider now owns 364,131 shares in the company, valued at approximately $1,340,002.08. The trade was a 2.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew W. Foehr sold 13,964 shares of OmniAb stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total value of $51,387.52. Following the sale, the chief executive officer now owns 3,798,682 shares in the company, valued at $13,979,149.76. This trade represents a 0.37 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 112,260 shares of company stock worth $376,601. Corporate insiders own 8.60% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on OABI. HC Wainwright reaffirmed a "buy" rating and set a $11.00 price target on shares of OmniAb in a report on Thursday, November 14th. Benchmark reaffirmed a "buy" rating and set a $8.00 price target on shares of OmniAb in a report on Thursday, November 14th.
Read Our Latest Stock Report on OmniAb
About OmniAb
(
Free Report)
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
See Also
Before you consider OmniAb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.
While OmniAb currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
